Polymorphisms of HER2 Ile655Val and cyclin D1 (CCND1) G870A are not associated with breast cancer risk but polymorphic allele of HER2 is associated with nodal metastases

Neoplasma

Volumn 55, Issue 2, 2008, Pages 87-95

  Naidu, R ^a   Yip, C H ^b,c   Taib, N A ^b,c  

^a MONASH UNIVERSITY MALAYSIA   (Malaysia)

^b UNIVERSITY OF MALAYA   (Malaysia)

^c UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

Author keywords

Breast cancer; Cyclin D1; Genetic polymorphism; HER2

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HISTOPATHOLOGY; HOMOZYGOTE; HUMAN; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PROGNOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; AGED; BREAST TUMOR; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; BREAST NEOPLASMS; CYCLIN D1; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTOR, ERBB-2;

EID: 48549103302     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. AKIYAMA T, SUDO C, OGAWARA H et al. The product of the human HER2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986; 232: 1644-1646
2. BARGMANN CI, HUNG MC, WEINBERG RA The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 1986; 319: 226-230
3. HELDIN CH Dimerization of cell surface receptors in signal transduction. Cell 1995; 80: 213-223
4. DOUGALL WC, QIAN X, PETERSON NC et al. The neuoncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene 1994; 9: 2109-2123 (Pubitemid 24228659)
5. ROSS JS, FLETCHER JA, LINETTE GP et al. The HER2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003; 8: 307-325
6. PAIK S, BRYANT J, TAN-CHIU E et al. HER2 and choice of adjuvant chemotherapy for breast cancer. National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 2000; 92: 1991-1998 (Pubitemid 32045895)
7. STERN DF, KAMPS MP, CAO H Oncogene activation of p185neu stimulates tyrosine phosphorylation in vivo. Mol Cell Biol 1988; 8: 3969-3973
8. PAPEWALIS J, NIKITIN A, RAJEWSKY MF G to A polymorphism at amino acid codon 655 of the human erbB-2/HER2 gene. Nucleic Acids Res 1991; 19: 5452
9. FLEISHMAN SJ, SCHLESSINGER J, BEN-TAL N A putative molecular-activation switch in the transmembrane domain of erbB2. Proc Natl Acad Sci USA 2002; 99: 15937-15940
10. XIE D, SHU XO, DENG Z et al. Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 2000; 92: 412-417 (Pubitemid 30154823)
11. MCKEAN-COWDIN R, KOLONEL LN, PRESS MF et al. Germ-line HER-2 variant and breast cancer risk by stage of disease. Cancer Res 2001; 61: 8393-8394 (Pubitemid 33131112)
12. PINTO D, VASCONCELOS A, COSTA S et al. HER2 polymorphism and breast cancer risk in Portugal. Eur J Cancer Prev 2004; 13: 177-181 (Pubitemid 38780673)
13. HISHIDA A, HAMAJIMA N, IWATA H et al. Re: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk [letter]. J Natl Cancer Inst 2002; 94: 1807-1808
14. WANG-GOHRKE S, CHANG-CLAUDE J Re: Populationbased, case-control study of HER2 genetic polymorphism and breast cancer risk [letter]. J Natl Cancer Inst 2001; 93: 1657-1659 (Pubitemid 33094876)
15. MILLIKAN R, EATON A, WORLEY K et al. HER2 codon 655 polymorphism and risk of breast cancer in African Americans and whites. Breast Cancer Res Treat 2003; 79: 355-364
16. BENUSIGLIO PR, LESUEUR F, LUCCARINI C et al. Common ERBB2 polymorphisms and risk of breast cancer in a white British population: a case-control study. Breast Cancer Res 2005; 7: R204-R209
17. SHERR CJ Cancer cell cycles. Science 1996; 274: 1672-1677
18. GILLET C, FANTI V, SMITH R et al. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 1994; 54: 1812-1817. (Pubitemid 24116192)
19. BARNES DM, GILLET C Cyclin D1 in breast cancer. Breast Cancer Res Treat 1998; 52: 1-15
20. BIECHE I, OLIVI M, NOGUES C et al. Prognostic value of cyclin D1 gene status in sporadic breast tumors, as determined by real-time quantitative PCR assays. Br J Cancer 2002; 86: 580-586
21. TERRY MB, GAMMON MD, SCHOENBERG JB et al. Oral contraceptive use and cyclin D1 overexpression in breast cancer among young women. Cancer Epidemiol Biomarkers Prev 2002; 11: 1100-1103 (Pubitemid 35192664)
22. NAIDU R, WAHAB NA, YADAV MM et al. Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters. Oncol Rep 2002; 9: 409-416
23. BETTICHER DC, THATCHER N, ALTERMATT HJ et al. Alternate splicing produces a novel cyclin D1 transcript. Oncogene 1995; 11: 1005-1011
24. KONG S, AMOS CI, LUTHRA R et al. Effects of cyclin D1 polymorphism on age of onset of hereditary nonpolyposis colorectal cancer. Cancer Res 2000; 60: 249-252
25. KONG S, WEI Q, AMOS CI et al. Cyclin D1 polymorphism and increased risk of colorectal cancer at young age. J Natl Cancer Inst 2001; 93: 1106-1108 (Pubitemid 32717544)
26. BALA S, PELTOMAKI P Cyclin D1 as a genetic modifier in hereditary nonpolyposis colorectal cancer. Cancer Res 2000; 61: 6042-6045.
27. ZHANG J, LI Y, WANG R et al. Association of cyclin D1 (G870A) polymorphism with susceptibility to esophageal and gastric cardiac carcinoma in a northern Chinese population. Int J Cancer 2003; 105: 281-284 (Pubitemid 36505334)
28. QIULING S, YUXIN Z, SUHUA Z et al. Cyclin D1 polymorphism and susceptibility to lung cancer in a Chinese population. Carcinogenesis 2003; 24: 1499-1503 (Pubitemid 37160840)
29. ZHENG Y, SHEN H, STURGIS EM et al. Cyclin D1 polymorphism and risk for squamous cell carcinoma of the head and neck: a case-control study. Carcinogenesis 2001; 22: 1195-1199 (Pubitemid 32737335)
30. WANG L, HABUCHI T, TAKAHASHI T et al. Cyclin D1 polymorphism is associated with an increased risk of urinary bladder cancer. Carcinogenesis 2002; 23: 257-264 (Pubitemid 34224000)
31. CATARINO R, MATOS A, PINTO D et al. Increased risk of cervical cancer associated with cyclin D1 gene A870G polymorphism. Cancer Genet Cytogenet 2005; 160: 49-54 (Pubitemid 40798136)
32. SONG JH, KIM CJ, CHO YG et al. Association of cyclin D1 G870A polymorphism with susceptibility to gastric cancers in Korean male patients. Neoplasma 2007; 54: 235-239
33. YU C, LU W, TAN W et al. Lack of association between CCND1 G870A polymorphism and risk of esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2003; 12: 176 (Pubitemid 36194012)
34. GRIEU F, MALANEY S, WARD R et al. Lack of association between CCND1 G870A polymorphism and the risk of breast and colorectal cancers. Anticancer Res 2003; 23: 4257-4259 (Pubitemid 37474930)
35. KRIPPL P, LANGSENLEHNER U, RENNER W et al. The 870G>A polymorphism of the cyclin D1 gene is not associated with breast cancer. Breast Cancer Res Treat 2003; 82: 165-168 (Pubitemid 37521972)
36. MCKAY JA, DOUGLAS JJ, ROSS VG et al. Cyclin D1 protein expression and gene polymorphism in colorectal cancer. Int J Cancer 2000; 88: 77-81 (Pubitemid 30677422)
37. LIM GC, HALIMAH Y Second Report of the National Cancer Registry. Cancer Incidence in Malaysia 2003. National Cancer Registry. Kuala Lumpur 2004
38. NAIDU R, HAR YC, TAIB NA P27 V109G Polymorphism is associated with lymph node metastases but not with increased risk of breast cancer. J Exp Clin Cancer Res 2007; 26: 133-140
39. MONTGOMERY KG, GERTIG DM, BAXTER SW et al. The HER2 I655V polymorphism and risk of breast cancer in women < age 40 years. Cancer Epidemiol Biomarkers Prev 2003; 12: 1109-1111 (Pubitemid 37310272)
40. RUTTER JL, CHATTERJEE N, WACHOLDER S et al. The HER2 I655V polymorphism and breast cancer risk in Ashkenazim. Epidemiology 2003; 14: 694-700 (Pubitemid 40417017)
41. ZUBOR P, VOJVODOVA A, DANKO J et al. HER-2 [Ile655Val] polymorphism in association with breast cancer risk: a population-based case-control study in Slovakia. Neoplasma 2006; 53: 49-55 (Pubitemid 43206939)
42. AKISIK E, DALAY N Estrogen receptor codon 594 and HER2 codon 655 polymorphisms and breast cancer risk. Exp Mol Pathol 2004; 76: 260-263
43. KAMALI-SARVESTANI E, TALEI AR, MERAT A Ile to Val polymorphism at codon 655 of HER2 gene and breast cancer risk in Iranian women. Cancer Lett 2004; 215: 83-87
44. AN HJ, KIM NK, OH D et al. HER2V655 genotype and breast cancer progression in Korean women. Pathol Int 2005; 55: 48-52
45. KESHAVA C, MCCANLIES EC, KESHAVA N et al. Distribution of HER2 (V655) genotypes in breast cancer cases and controls in the United States. Cancer Lett 2001; 173: 37-41
46. KALEMI TG, LAMBROPOULOS AF, GUEORGUIEV M et al. The association of p53 mutations and p53 codon 72, HER2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece. Cancer Lett 2005; 222: 57-65
47. BAXTER SW, CAMPBELL IG Re: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk [letter]. J Natl Cancer Inst 2001; 93: 557-559 (Pubitemid 32318438)
48. FORSTI A, ANGELINI S, FESTA F et al. Single nucleotide polymorphisms in breast cancer. Oncol Rep 2004; 11: 917-922
49. SHU XO, MOORE DB, CAI Q et al. Association of cyclin D1 genotype with breast cancer risk and survival. Cancer Epidemiol Biomarkers Prev 2005; 14: 91-97 (Pubitemid 40165288)
50. CESCHI M, SUN CL, VAN DEN BERG D et al. The effect of cyclin D1 (CCND1) G870A-polymorphism on breast cancer risk is modified by oxidative stress among Chinese women in Singapore. Carcinogenesis 2005; 26: 1457-1464
51. HOLLEY SL, MATTHIAS C, JAHNKE V et al. Association of cyclin D1 polymorphism with increased susceptibility to oral squamous cell carcinoma. Oral Oncol 2005; 41: 156-160 (Pubitemid 40202881)
52. ZHANG YJ, CHEN SY, CHEN CJ et al. Polymorphisms in cyclin D1 gene and hepatocellular carcinoma. Mol Carcinog 2002; 3: 125-129 (Pubitemid 34113201)
53. KANG S, KIM JW, PARK NH Cyclin D1 polymorphism and the risk of endometrial cancer. Gynecol Oncol 2005; 97: 431-435 (Pubitemid 40614886)
54. WANG L, HABUCHI T, MITSUMORI K, LI Z et al. Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism. Int J Cancer 2003; 103: 116-120 (Pubitemid 35424214)
55. LE MARCHAND L, SEIFRIED A, LUM-JONES A et al. Association of the cyclin D1 A870G polymorphism with advanced colorectal cancer. JAMA 2003; 290: 2843-2848 (Pubitemid 37509493)
56. JIANG J, WANG J, SUZUKI S et al. Elevated risk of colorectal cancer associated AA genotype of the cyclin D1 A870G polymorphism in an Indian population. J Cancer Res Clin Oncol 2006; 132: 193-199
57. NISHIMOTO IN, PINHEIRO NA, ROGATTO SR et al. Cyclin D1 gene polymorphism as a risk factor for squamous cell carcinoma of the upper aerodigestive system in non-alcoholics. Oral Oncol 2004; 40: 604-610
58. JEON YT, KIM JW, SONG JH et al. Cyclin D1 G870A polymorphism and squamous cell carcinoma of the uterine cervix in Korean women. Cancer Lett 2005; 223: 259-263
59. SATHYAN KM, NALINAKUMARI KR, ABRAHAM T et al. Influence of single nucleotide polymorphisms in H-Ras and cyclin D1 genes on oral cancer susceptibility. Oral Oncol 2006; 42: 607-613
60. SIMPSON DJ, FRYER AA, GROSSMAN AB et al. Cyclin D1 (CCND1) genotype is associated with tumour grade in sporadic pituitary adenomas. Carcinogenesis 2001; 22: 1801-1807
61. DHAR KK, BRANIGAN K, HOWELLS RE et al. Prognostic significance of cyclin D1 gene (CCND1) polymorphism in epithelial ovarian cancer. Int J Gynecol Cancer 1999; 9: 342-347 (Pubitemid 29399370)
62. MATTHIAS C, BRANIGAN K, JAHNKE V et al. Polymorphism within the cyclin D1 gene is associated with prognosis in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 1998; 4: 2411-2418. Erratum in: Clin Cancer Res 1999; 5: 222
63. SAWA H, OHSHIMA TA, UKITA H et al. Alternatively spliced forms of cyclin D1 modulate entry into the cell cycle in an inverse manner. Oncogene 1998; 16: 1701-1712
64. BENLIMAME N, HE Q, JIE S et al. FAK signaling is critical for ErbB-2/ErbB-3 receptor cooperation for oncogenic transformation and invasion. J Cell Bio 2005; 171: 505-516